RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors.
Sign Up to like & getrecommendations! Published in 2023 at "Current cancer drug targets"
DOI: 10.2174/1568009623666230418101511
Abstract: BACKGROUND Breast and ovarian tumors with pathogenic variants in BRCA1 or BRCA2 genes are more sensitive to poly (ADP-ribose) polymerase inhibitors (PARPi) treatment than wild-type tumors. Pathogenic variants in non-BRCA1/2 homologous recombination repair genes (HRR)… read more here.
Keywords: breast cancer; t47d; rad50; rad50 deficient ... See more keywords